A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine

Novo Nordisk

Status: Completed

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Insulin detemir

Study type: Observational

Funder types: Industry

Identifiers

NCT03960814

EUPAS29708 (Registry Identifier)

U1111-1233-0930 (Other Identifier)

NN304-4528

Details and patient eligibility

About

This study will examine the influence of the basal insulins detemir and glargine on risk of cardiovascular death and death from all causes in patients treated by their general practitioner in United Kingdom (UK). The data for this study will be drawn from the Clinical Practice Research Datalink (CPRD) Register.

Enrollment: 12,847 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis (ever) of type 2 diabetes
• Prescription (ever) of basal insulins glargine or detemir
• Insulin-naïve until initiation of basal insulins glargine or detemir
• Aged 40 years or older at start of observation period

Exclusion criteria

• Diagnosis of type 1 diabetes

Trial design

12,847 participants in 1 patient group

Cohort 1

Description:

New users of basal insulins glargine and detemir

Treatment:

Drug: Insulin detemir